<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0025">
 <label>Table 5</label>
 <caption>
  <p>Impacts of CCR5Δ32 on HCV infection.</p>
 </caption>
 <alt-text id="at0105">Table 5</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Population</th>
    <th align="left">Sample</th>
    <th align="left">Main findings</th>
    <th align="left">References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">German</td>
    <td align="left">153 HCV-infected individuals; 102 HIV-infected individuals; 130 HCV/HIV co-infected individuals; 102 non-infected individuals</td>
    <td align="left">The CCR5Δ32 polymorphism (Δ32 allele and homozygous genotype) was associated with increased susceptibility to HCV infection; The CCR5Δ32 homozygous genotype was associated with increased HCV loads</td>
    <td align="left">
     <xref rid="bib1615" ref-type="bibr">Woitas et al. (2002)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">German</td>
    <td align="left">156 chronic HCV-infected individuals</td>
    <td align="left">The CCR5Δ32 allele was associated with reduced response rates to interferon-α monotherapy</td>
    <td align="left">
     <xref rid="bib0015" ref-type="bibr">Ahlenstiel et al. (2003)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Caucasian</td>
    <td align="left">62 chronic HCV-infected individuals; 119 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td>
    <td align="left">
     <xref rid="bib0510" ref-type="bibr">Glas et al. (2003)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">European</td>
    <td align="left">544 HCV-infected individuals with persistent infection; 128 individuals who cleared the virus (547 individuals were genotyped for CCR5Δ32)</td>
    <td align="left">The CCR5Δ32 polymorphism was associated with reduced portal inflammation and increased liver fibrosis</td>
    <td align="left">
     <xref rid="bib0625" ref-type="bibr">Hellier et al. (2003)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Information not available</td>
    <td align="left">235 chronic HCV-infected individuals; 96 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection or HCV-related disease progression</td>
    <td align="left">
     <xref rid="bib0970" ref-type="bibr">Mangia et al. (2003)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Slovenian</td>
    <td align="left">150 HCV-infected individuals; 101 HIV-infected individuals; 385 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection</td>
    <td align="left">
     <xref rid="bib1170" ref-type="bibr">Poljak et al. (2003)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">American</td>
    <td align="left">417 individuals with liver disease (including 339 HCV-infected individuals); 2380 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td>
    <td align="left">
     <xref rid="bib1175" ref-type="bibr">Promrat et al. (2003)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Caucasian (American; European)</td>
    <td align="left">1419 hemophiliacs (stratified in the analyzes according to serological status for HCV and HIV)</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection; This study indicated that the results of 
     <xref rid="bib1615" ref-type="bibr">Woitas et al. (2002)</xref> was affected by the inclusion of hemophiliacs in the HCV-infected group
    </td>
    <td align="left">
     <xref rid="bib1670" ref-type="bibr">Zhang et al. (2003)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Japanese</td>
    <td align="left">105 chronic HCV-infected individuals; 53 non-infected individuals</td>
    <td align="left">The CCR5Δ32 allele was not detected in any individuals included in the study</td>
    <td align="left">
     <xref rid="bib0780" ref-type="bibr">Konishi et al. (2004)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">German</td>
    <td align="left">257 chronic HCV-infected individuals; 250 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td>
    <td align="left">
     <xref rid="bib0995" ref-type="bibr">Mascheretti et al. (2004)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Spanish</td>
    <td align="left">139 HCV-infected individuals; 100 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection or liver injury</td>
    <td align="left">
     <xref rid="bib1240" ref-type="bibr">Ruiz-Ferrer et al. (2004)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Israeli</td>
    <td align="left">127 chronic HCV-infected individuals; 48 HCV-infected individual who had undergone liver transplantation due to liver cirrhosis; 75 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection; The CCR5Δ32 allele was associated with reduced liver inflammation</td>
    <td align="left">
     <xref rid="bib1590" ref-type="bibr">Wald et al. (2004)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">German</td>
    <td align="left">333 HCV-infected individuals; 125 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection; No major association between the CCR5Δ32 and HCV-related liver disease or therapy response</td>
    <td align="left">
     <xref rid="bib1600" ref-type="bibr">Wasmuth et al. (2004)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Irish</td>
    <td align="left">196 chronic HCV-infected individuals; 88 individuals who cleared the virus; 120 non-infected individuals</td>
    <td align="left">The CCR5Δ32 polymorphism was associated with HCV clearance and less severe hepatic inflammatory scores</td>
    <td align="left">
     <xref rid="bib0545" ref-type="bibr">Goulding et al. (2005)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Belgian</td>
    <td align="left">163 HCV-infected individuals; 310 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection</td>
    <td align="left">
     <xref rid="bib1490" ref-type="bibr">Thoelen et al. (2005)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Information not available</td>
    <td align="left">252 chronic HCV-infected individuals; 408 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection, HCV-related liver disease or therapy response</td>
    <td align="left">
     <xref rid="bib0555" ref-type="bibr">Goyal et al. (2006)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Information not available</td>
    <td align="left">21 HCV-infected hemophiliacs</td>
    <td align="left">The CCR5Δ32 allele was associated with reduced anti-viral (mediated by interferon-γ) response</td>
    <td align="left">
     <xref rid="bib0025" ref-type="bibr">Ahlenstiel et al. (2009)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">German</td>
    <td align="left">277 chronic HCV-infected individuals; 119 individuals who cleared the virus; 105 non-infected individuals</td>
    <td align="left">The CCR5Δ32 wild-type genotype was associated with spontaneous viral clearance. Therefore, CCR5Δ32 allele can be considered a risk factor for persistent infection</td>
    <td align="left">
     <xref rid="bib1075" ref-type="bibr">Nattermann et al. (2011)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Egyptian</td>
    <td align="left">190 
     <italic>Schistosoma mansoni</italic>/HCV co-infected individuals; 220 
     <italic>S. mansoni</italic>-infected individuals
    </td>
    <td align="left">The CCR5Δ32 allele was associated with spontaneous viral clearance in co-infected individuals</td>
    <td align="left">
     <xref rid="bib0435" ref-type="bibr">El-Moamly et al. (2013)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Australian; European</td>
    <td align="left">813 chronic HCV-infected individuals; 836 non-infected individuals</td>
    <td align="left">The CCR5Δ32 homozygous genotype was associated with chronic HCV infection (especially in Europeans); No association between the CCR5Δ32 and therapy response</td>
    <td align="left">
     <xref rid="bib1435" ref-type="bibr">Suppiah et al. (2013)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Swiss; Italian</td>
    <td align="left">1290 chronic HCV-infected individuals; 160 individuals who cleared the virus</td>
    <td align="left">The CCR5Δ32 allele was associated with decreased rates of spontaneous viral clearance; No association between the CCR5Δ32 and HCV-related liver disease or therapy response</td>
    <td align="left">
     <xref rid="bib1030" ref-type="bibr">Morard et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Turkish</td>
    <td align="left">58 chronic HCV-infected individuals; 58 non-infected individuals</td>
    <td align="left">The CCR5Δ32 allele was associated with higher HCV load and reduced histology activity index in liver samples</td>
    <td align="left">
     <xref rid="bib1650" ref-type="bibr">Yilmaz et al. (2014)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Iranian</td>
    <td align="left">100 HCV-infected individuals; 100 non-infected individuals</td>
    <td align="left">The CCR5Δ32 was not detected in any individuals included in the study</td>
    <td align="left">
     <xref rid="bib0130" ref-type="bibr">Bineshian et al. (2018)</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Brazilian</td>
    <td align="left">674 HCV-infected individuals; 104 HCV/HIV co-infected individuals; 300 HIV-infected individuals; 274 non-infected individuals</td>
    <td align="left">No association between the CCR5Δ32 and susceptibility to HCV infection or HCV/HIV co-infection; No association between the CCR5Δ32 and HCV-related fibrosis, cirrhosis or hepatocarcinoma</td>
    <td align="left">
     <xref rid="bib0410" ref-type="bibr">Ellwanger et al. (2018b)</xref>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
